Equities analysts expect Sol Gel Technologies Ltd (NASDAQ:SLGL) to announce $50,000.00 in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Sol Gel Technologies’ earnings. The business is scheduled to issue its next earnings results on Monday, March 25th.
On average, analysts expect that Sol Gel Technologies will report full year sales of $180,000.00 for the current financial year. For the next fiscal year, analysts forecast that the firm will post sales of $310,000.00. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that cover Sol Gel Technologies.
Get Sol Gel Technologies alerts:Sol Gel Technologies (NASDAQ:SLGL) last released its quarterly earnings results on Tuesday, November 13th. The company reported ($0.40) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.16. The company had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.05 million.
Several research firms have recently commented on SLGL. HC Wainwright set a $21.00 price target on Sol Gel Technologies and gave the stock a “buy” rating in a research note on Tuesday, October 9th. Zacks Investment Research upgraded Sol Gel Technologies from a “hold” rating to a “buy” rating and set a $7.75 price objective for the company in a research report on Tuesday, November 20th. Finally, ValuEngine cut Sol Gel Technologies from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $16.55.
Shares of Sol Gel Technologies stock traded down $0.08 during trading hours on Friday, hitting $5.91. 4,410 shares of the company were exchanged, compared to its average volume of 4,881. Sol Gel Technologies has a 1 year low of $5.41 and a 1 year high of $16.48. The stock has a market capitalization of $113.35 million and a PE ratio of -1.18.
An institutional investor recently bought a new position in Sol Gel Technologies stock. Raymond James & Associates bought a new stake in shares of Sol Gel Technologies Ltd (NASDAQ:SLGL) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 13,260 shares of the company’s stock, valued at approximately $102,000. Raymond James & Associates owned 0.07% of Sol Gel Technologies at the end of the most recent quarter. 20.32% of the stock is owned by institutional investors and hedge funds.
Sol Gel Technologies Company Profile
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.
Read More: Technical Analysis of Stocks, How Can It Help
Get a free copy of the Zacks research report on Sol Gel Technologies (SLGL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment